1,000 people. $100 each. One opportunity to move this technology into clinical validation.

About a year ago, I received a phone call that changed my life.

My mother told me that my 7-year-old nephew was living with brain lesions and that doctors had spent months trying to determine exactly what was happening.

She said, “Jeremy, you need to do something.”

I told her, “Mom, I’m a mathematician. I’m not a doctor.”

She answered, “Yes, but you’re the smartest person I know.”

That conversation became the beginning of Salynt.

Today, my team and I have the opportunity to conduct Salynt’s first clinical validation study focused on brain tumors.

Why This Matters

Nearly 5,000 children and adolescents in the United States are expected to be diagnosed with a primary brain tumor this year. Brain tumors remain the leading cause of childhood cancer-related death.

Successfully developing and validating this technology would bring us closer to helping my nephew and thousands of other children and families searching for clearer answers.

Salynt is building an AI-powered neuroimaging platform designed to help clinicians analyze complex brain scans, measure tumors and create structured clinical evidence that can support better-informed decisions.

Why We Need $100,000

Salynt must provide at least $100,000 to help move this study forward.

Contributions will support:

• Clinical-study preparation and execution
• Secure medical-imaging infrastructure
• AI validation and product readiness
• Security, privacy and compliance work
• Clinical and regulatory documentation

I have invested and given up everything I can personally to make this happen. Now, I’m asking my community and network to stand with us.

I believe God can move through 1,000 people giving $100, but anything helps.

If you can contribute, thank you.

If you cannot contribute, please share this campaign. Your share may reach someone who can help us get there.

One child inspired this mission. Together, we can build something that may help thousands more.

Transparency

Salynt, Inc. is a for-profit healthcare technology company. Contributions are not tax-deductible and do not provide equity, ownership or a financial return. Funds will support Salynt’s brain-tumor neuroimaging research and clinical-validation expenses across pediatric and adult cases. The proposed institutional study remains subject to final study design, institutional approvals and applicable agreements.